Search Result

Results for "

ABHD6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FAAH (3) Histamine Receptor (1) MAGL (17) Small Interfering RNA (siRNA) (1)
By Research Areas:	Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (7)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132246

WWL123 analogue-1	MAGL	Neurological Disease
WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective *ABHD6* inhibitor with an IC₅₀ of 430 nM . WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice .

HY-RS00097

ABHD6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABHD6 Human Pre-designed siRNA Set A contains three designed siRNAs for ABHD6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABHD6 Human Pre-designed siRNA Set A ABHD6 Human Pre-designed siRNA Set A

HY-117722

JW 618

MAGL Others

JW 618 is a selective ABHD6 inhibitor, with IC₅₀s of 38 and 13 nM for mouse and rat ABHD6 .

JW 618	MAGL	Others
JW 618 is a selective *ABHD6* inhibitor, with IC₅₀s of 38 and 13 nM for mouse and rat ABHD6 .

HY-152152

JZP-MA-13	MAGL	Neurological Disease
JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .

HY-116793

Dimepiperate

MY 93; Yukamate
MAGL Others

Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6 .

Dimepiperate MY 93; Yukamate	MAGL	Others
Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6 .

HY-152148

JZP-MA-11	MAGL	Neurological Disease
JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC₅₀ value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .

HY-18544

AA38-3

MAGL FAAH Metabolic Disease

AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .

AA38-3	MAGL FAAH	Metabolic Disease
AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .

HY-124314

LEI-106	MAGL	Metabolic Disease
LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor with an IC₅₀ of 18 nM for DAGL-α and a K_i of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [ ¹⁴C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a K_i of 0.7 μM .

HY-125143

ABC34	MAGL	Metabolic Disease
ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both *ABHD6* and PPT122 .

HY-100337

WWL70

2 Publications Verification

MAGL Neurological Disease

WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 70 nM.
HY-114926

KT185

MAGL Neurological Disease

KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC₅₀ 0.21 nM in Neuro2A cells .
HY-120177

KT182

MAGL Others

KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC₅₀ of 0.24 nM in Neuro2A cells .
HY-120215

KT203

MAGL Metabolic Disease

KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC₅₀ of 0.31 nM in Neuro2A cells .

WWL70 2 Publications Verification	MAGL	Neurological Disease
WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 70 nM.

KT185	MAGL	Neurological Disease
KT185 is an orally-bioavailable, brain-penetrant and selective *ABHD6* inhibitor, with an IC₅₀ 0.21 nM in Neuro2A cells .

KT182	MAGL	Others
KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC₅₀ of 0.24 nM in Neuro2A cells .

KT203	MAGL	Metabolic Disease
KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC₅₀ of 0.31 nM in Neuro2A cells .

HY-110178

WWL123	MAGL	Inflammation/Immunology
WWL123, a carbamate-based compound, is a potent and selective *ABHD6* inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .

HY-101457

JZP-430
JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC₅₀ of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .

HY-136924

FP-Biotin	FAAH	Others
FP-biotin is a potent organophosphorus toxicant, well-suited for searching for new biomarkers of organophosphorus toxicants exposure. FP-Biotin quantifies FAAH, ABHD6, and MAG-lipase activity. FP-biotin is used for studies with plasma because biotinylated peptides are readily purified by binding to immobilized avidin beads .

HY-120171

DH-376	MAGL	Metabolic Disease
DH-376 is a potent diacylglycerol lipase inhibitor with pIC₅₀ values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice . DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-110148

WWL113	Others	Metabolic Disease
WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC₅₀ values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases) .

HY-103463

SA57	FAAH MAGL	Neurological Disease
SA57 is a potent, selective FAAH inhibitor with IC₅₀s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC₅₀s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC₅₀ of 850 nM), but not other brain serine hydrolases .

HY-121422

JZP-361	MAGL Histamine Receptor	Inflammation/Immunology
JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC₅₀ of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

DH-376		Alkynes
DH-376 is a potent diacylglycerol lipase inhibitor with pIC₅₀ values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice . DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.